Traffic Lights - Latest Updates

Last updated: 14/05/2021

Other updates on this site
Drug Name Classification Clinical Indication Comments
ALBUTREPENONACOG ALPHA (Idelvion®) (NEW) Red Prophylaxis and treatment of bleeding in Haemophilia B
ALPHA-TOCOPHEROL (VITAMIN E) (NEW) Red When given with pentoxifylline or the treatment of persistently thin endometrium during IVF therapy
AMIKACIN (Arikayce Liposomal®) (NEW) Black Non-tuberculous mycobacterial (NTM) lung infections

Not yet reviewed

ANAKINRA (Kineret®) (NEW) Red Still’s disease and juvenile idiopathic arthritis

In line with NICE TA685

Implementation date 30th June

ANTITHROMBIN recombinant (UPDATED) Red Congenital antithrombin deficiency
AVATROMBOPAG (Doptelet®) (NEW) Black Severe thrombocytopenia

Not yet reviewed

BARICITINIB (NEW) Red Moderate to severe atopic dermatitis

In line with NICE TA681

Implementation date 3rd June 2021


In line with NICE TA672

BUDESONIDE (1mg orodipersible tablet) (Jorveza®) (UPDATED) Red For treatment of eosinophilic eosinophagitis in adults and children

Used by Turning Point . If a patient is admitted to hospital contact turning point for advice about alternatives:

0116 3732117 – Direct dial to prescribing team

0116 3732108 – Direct Dial to Clinical Admin

0330 303 6000 – Main Switchboard

CAPLACIZUMAB (Cablivi®) (UPDATED) Red Acquired TTP

In line with NICE TA667 

Implementation date 16th March 2021

CEFIDEROCOL SULFATE TOSYLATE (Fetcroja®) Black Treatment of infections due to aerobic Gram-negative organisms

Not yet reviewed

CICLOSPORIN EYEDROPS (Verkazia®) (NEW) Amber Simple Treatment of severe vernal keratoconjunctivitis (VKC) in children from 4 years of age and adolescents
COLISTIN (NEW) Red Nebulised for Cystic fibrosis
COLISTIN (Colomycin® and Promixin ®) (UPDATED) Amber Full SCA Nebulised for cystic fibrosis

Historic patients only. Must be prescribed by brand as the brands are not interchangeable.

Dapagliflozin (Forxiga®) (NEW) Amber Simple Chronic Heart failure with reduced ejection fraction

In line with NICE TA679

ERENUMAB 70mg injection (Aimovig®) (UPDATED) Red Migraine prophylaxis

In line with NICE TA682

Implementation date 10th June 2021

FILGOTINIB (Jyseleca®) (NEW) Red Moderate to severe arthritis

In line with NICE TA676

Implementation date 24th May 2021


Not yet reviewed

GALCANEZUMAB (Emgality ®) (UPDATED) Red Migraine prophylaxis

In line with NICE TA659


Not yet reviewed

INCLIRISAN (Leqivo®) (NEW) Black Primary hypercholesteraima and mixed dyslipidaemia

Not yet reviewed

INDACATEROL/GLYCOPYRRONIUM/ MOMETASONE (Enerzair Breezhaler) (NEW) Black Maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.

Not yet reviewed

INDACATEROL/MOMETASONE dry powder inhaler (Atectura Breezhaler®) (NEW) Black Maintenance treatment of asthma in adults and adolescents 12 years of age and older

Not yet reviewed

INHALED DRY POWDER BUDESONIDE (NEW) Green Covid 19 treatment commenced in primary care for patients 50 years and over.

In line with CAS alert 103154 

See CAS alert and alert attachments for more information including eligibility and duration of treatment and  also see the formulary


Klean-Prep® (UPDATED) Green Bowel cleansing before lower GI endoscopy (second line)

In line with prism pathway (currently under development, traffic light change in readiness)

LIDOCAINE HYDROCHLORIDE + PHENAZONE EAR DROPS (Otigo®) (NEW) Black Local symptomatic treatment and relief of pain in specified diseases of the middle ear without tympanic perforation.

Not yet reviewed

LIDOCAINE Patch (UPDATED) Black All indications except post herpetic neuralgia

New patients initially. Further advice to come regarding historic patients

LIRAGLUTIDE (Saxenda®) (UPDATED) Red Obesity as part of a tier 3 specialist weight management service

In line with NICE TA664

LUSUTROMBOPAG (Mulpleo®) (NEW) Black Severe thrombocytopenia

Not yet reviewed

Moviprep® (UPDATED) Green Bowel cleansing before lower GI endoscopy (first line)

In line with prism pathway (currently under development, traffic light change in readiness)

NALDEMEDINE TOSYLATE (Rizmoic®) (UPDATED) Green opioid-induced constipation

As per NICE TA651.


ONASEMNOGENE ABEPARVOVEC (Zolgensma®) (NEW) Black 5q spinal muscular atrophy (SMA)

Not yet reviewed

OZANIMOD (Zeposia®) (NEW) Black Adults with active disease as part of relapsing-remitting Multiple Sclerosis.

Not yet reviewed

PENTOXIFYLLINE (Trental®) (NEW) Red When given with alpha tocopherol (vitamin E) for the treatment of persistently thin endometrium during IVF therapy
PRIDINOL (Myopridin®) (NEW) Black Central and peripheral muscle spasms, lumbar pain, torticollis and general muscle pain

Not yet reviewed

Salmeterol and Fluticasone inhalation powder (Fixkoh Airmaster®) (NEW) Black Asthma and COPD

Not yet reviewed

SIPONIMOD FUMARIC ACID (Mayzent®) (UPDATED) Red Secondary progressive multiple sclerosis in adults

In line with NICE TA656

SODIUM CROMOGLICATE CAPSULES (Nalcrom®) (UPDATED) Amber Simple Mast cell stabalisation including Haematology and food allergy indications
SUGAMMADEX (Bridion®) (UPDATED) Red Reversal of neuromuscular blockage induced by rocuronium or vecuronium
TACROLIMUS (Advagraf®) (NEW) Red Continuation of hepatic transplant immunosuppression for patients transferred from out of area tertiary centre only
TIZANIDINE (UPDATED) Amber Simple Generalised spasticity for patients who have been stabilised on a dose

To revert to secondary care only, when there are any dose changes and doses of 12mg a day or more require secondary care prescribing for 4 months whilst monthly LFTs are undertaken by secondary care.

UPADACITINIB (RINVOQ®) (UPDATED) Red Rheumatoid arthritis

In line with NICE TA665

VIGABATRIN (UPDATED) Amber Simple Epilepsy

Clarification of historical status

VOLANESORSEN (Waylivra®) (NEW) Red Familial chylomicronaemia syndrome in adults

In line with NICE HST13

Other Updates on this Website

Recent documents from LMSG and TAS

About the Leicestershire Medicines Strategy Group

In common with other local health communities, the Leicestershire Medicines Strategy Group (LMSG) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.

Leicestershire Health Community comprises the three Clinical Commissioning Groups, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LMSG has been in place since 2005. Learn more